Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994155 | 0.91 | PTGDR2 (0.51) | PTGDR2MEN1KMT2ANR1I2TSHR | |
| SCHEMBL2348067 | 0.87 | MEN1 (0.50) | PTGDR2MEN1KMT2ATSHRPOLB | |
| SCHEMBL1990403 | 0.85 | PTGDR2 (0.43) | PTGDR2MEN1KMT2ATSHRPOLB | |
| SCHEMBL1987844 | 0.82 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL15793498 | 0.82 | PTGDR2 (0.71) | PTGDR2MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL3421956 | 0.82 | PTGDR2 (0.43) | PTGDR2POLBMAPK1ALDH1A1MAPT | |
| SCHEMBL1990235 | 0.81 | PTGDR2 (0.45) | PTGDR2MEN1KMT2APOLBMAPK1 | |
| SCHEMBL1992776 | 0.80 | MAPT (0.49) | PTGDR2MEN1KMT2ANR1I2TSHR | |
| SCHEMBL1989639 | 0.80 | MEN1 (0.46) | PTGDR2MEN1KMT2ATSHRPOLB | |
| SCHEMBL1992257 | 0.80 | PTGES2 (0.47) | MEN1KMT2ANR1I2PTGES2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8349897-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2013-01-08 | — | — | US | disclosed |
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| US-8008350-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| EP-1937633-B8 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| EP-1937633-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| EP-1937633-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039741-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGDR2 568/4885MEN1 4615/4885KMT2A 1225/4885 |
| US-20110152374-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGDR2 568/4885MEN1 4615/4885KMT2A 1225/4885 |
| US-20090036535-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGDR2 568/4885MEN1 4615/4885KMT2A 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.